Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Intravenous Immunoglobulin (IVIG)
Treatment for Encephalitis
Typical Dosage: 0.4g/kg IV daily for 5 days
Effectiveness
80%
Safety Score
55%
Clinical Trials
12
Participants
2.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
0.4g/kg IV daily for 5 days
Time to Effect
5-10 days
Treatment Duration
5 days, may repeat
Evidence Quality
MODERATENumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
50(Treat 50 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$20,000
Monitoring:$10,000
Side Effect Mgmt:$500
Total Annual:$30,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$95,000/QALY
QALYs Gained
7
Outcome-Based Costs
Cost per Responder
$50,833
Cost per Remission
$67,778
Intravenous Immunoglobulin (IVIG) Outcomes
for Encephalitis
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+60%
Remission Rate
+45%
Common Side Effects
Headache
+15%
Fever/Chills
+10%
Aseptic meningitis
+2%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
2 active trials recruiting for Intravenous Immunoglobulin (IVIG) in Encephalitis
IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2
NCT03194815RECRUITINGPHASE2
70 participants
INTERVENTIONAL
Cambridge, United Kingdom +9 more
Started: Nov 1, 2017
Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis
NCT06867991RECRUITINGPHASE3
200 participants
INTERVENTIONAL
Zhengzhou, China +1 more
Started: Nov 8, 2024
Completed Clinical Trials
7 completed trials for Intravenous Immunoglobulin (IVIG) in Encephalitis
Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis
NCT01856205COMPLETEDPHASE2
22 participants
INTERVENTIONAL
Kathmandu, Nepal +1 more
Started: May 1, 2009
Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants
NCT06753955COMPLETEDPHASE1
7 participants
INTERVENTIONAL
Melbourne, Australia
Started: Feb 25, 2025
Investigating the Role of Early Intravenous Immunoglobulin Treatment for Children With Encephalitis
NCT02308982COMPLETEDPHASE3
18 participants
INTERVENTIONAL
Aberdeen, United Kingdom +24 more
Started: Jan 1, 2016
CPI Combination Therapy for Autoimmune Encephalitis
NCT03542279COMPLETEDNA
70 participants
INTERVENTIONAL
Beijing, China
Started: Nov 25, 2020
To Explore Cognitive Neural Mechanism of Autoimmune Encephalitis by Using Neuropsychological Tests and Multi-modal MRI
NCT03530462COMPLETED
22 participants
OBSERVATIONAL
Hangzhou, China
Started: Apr 7, 2017
IVIG - West Nile Encephalitis: Safety and Efficacy
NCT00068055COMPLETEDPHASE1, PHASE2
62 participants
INTERVENTIONAL
Birmingham, United States +68 more
Started: Sep 1, 2003
Omr-IgG-am(Trademark) for Treating Patients With or at High Risk for West Nile Virus Disease
NCT00069316COMPLETEDPHASE2
2 participants
INTERVENTIONAL
Bethesda, United States
Started: Sep 22, 2003